IL307726A - Multimeric oligonucleotides with reduced renal clearance - Google Patents
Multimeric oligonucleotides with reduced renal clearanceInfo
- Publication number
- IL307726A IL307726A IL307726A IL30772623A IL307726A IL 307726 A IL307726 A IL 307726A IL 307726 A IL307726 A IL 307726A IL 30772623 A IL30772623 A IL 30772623A IL 307726 A IL307726 A IL 307726A
- Authority
- IL
- Israel
- Prior art keywords
- kidney clearance
- decreased kidney
- multimeric oligonucleotides
- multimeric
- oligonucleotides
- Prior art date
Links
- 108091034117 Oligonucleotide Proteins 0.000 title 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title 1
- 230000003247 decreasing effect Effects 0.000 title 1
- 210000003734 kidney Anatomy 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3519—Fusion with another nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
- C12N2310/3533—Halogen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/51—Physical structure in polymeric form, e.g. multimers, concatemers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
- C12N2320/53—Methods for regulating/modulating their activity reducing unwanted side-effects
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762455231P | 2017-02-06 | 2017-02-06 | |
| US201762522363P | 2017-06-20 | 2017-06-20 | |
| US201762561853P | 2017-09-22 | 2017-09-22 | |
| PCT/US2018/017062 WO2018145086A1 (en) | 2017-02-06 | 2018-02-06 | Multimeric oligonucleotides having decreased kidney clearance |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL307726A true IL307726A (en) | 2023-12-01 |
Family
ID=63039118
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL307726A IL307726A (en) | 2017-02-06 | 2018-02-06 | Multimeric oligonucleotides with reduced renal clearance |
| IL267806A IL267806B2 (en) | 2017-02-06 | 2018-02-06 | Multimeric oligonucleotides having decreased kidney clearance |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL267806A IL267806B2 (en) | 2017-02-06 | 2018-02-06 | Multimeric oligonucleotides having decreased kidney clearance |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11078484B2 (https=) |
| EP (1) | EP3576752A4 (https=) |
| JP (1) | JP7183167B2 (https=) |
| KR (2) | KR102776167B1 (https=) |
| CN (1) | CN110248665A (https=) |
| AU (1) | AU2018215684B2 (https=) |
| CA (1) | CA3051480A1 (https=) |
| IL (2) | IL307726A (https=) |
| MX (1) | MX2019009347A (https=) |
| SG (1) | SG11201906728TA (https=) |
| WO (1) | WO2018145086A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101141544B1 (ko) | 2009-03-13 | 2012-05-03 | 한국과학기술원 | 에스아이알엔에이 다중 접합체 및 이의 제조방법 |
| IL316159A (en) * | 2015-06-15 | 2024-12-01 | Mpeg La Llc | Defined Oligonucleotide Multimers and Methods for Manufacture Thereof |
| SG11201906728TA (en) | 2017-02-06 | 2019-08-27 | Mpeg La Llc | Multimeric oligonucleotides having decreased kidney clearance |
| EP3935168A4 (en) * | 2019-03-04 | 2024-04-10 | Mpeg La, LLC | MULTIMERIC OLIGONUCLEOTIDES WITH IMPROVED BIOACTIVITY |
| JP2022528487A (ja) * | 2019-03-29 | 2022-06-13 | ユニバーシティ・オブ・マサチューセッツ | Ｃ９ｏｒｆ７２のオリゴヌクレオチドベースの調節 |
| US11629347B2 (en) | 2019-05-06 | 2023-04-18 | University Of Massachusetts | Anti-C9ORF72 oligonucleotides and related methods |
| JP2022543191A (ja) * | 2019-07-30 | 2022-10-11 | エムペグ エルエイ リミテッド ライアビリティ カンパニー | 増強された生理活性を有する多量体オリゴヌクレオチドの皮下送達 |
| WO2021026476A1 (en) * | 2019-08-08 | 2021-02-11 | Mpeg La, L.L.C. | Complement targeting with multimeric oligonucleotides |
| KR20230003579A (ko) * | 2020-04-30 | 2023-01-06 | 엠펙 엘에이, 엘.엘.씨. | 분할된 가닥을 갖는 다량체 올리고뉴클레오타이드 |
| EP4149557A4 (en) * | 2020-05-13 | 2025-01-15 | The University of North Carolina at Chapel Hill | Nucleic acid ligand conjugates and use thereof for delivery to cells |
| CA3178559A1 (en) * | 2020-05-19 | 2021-11-25 | Jonathan Miles Brown | Orthogonally linked multimeric oligonucleotides |
| WO2024228030A2 (en) | 2023-05-04 | 2024-11-07 | Argonaute RNA Limited | Dual silencing |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9207381D0 (en) | 1992-04-03 | 1992-05-13 | Ici Plc | Synthesis of oligonucleotides |
| AU760549B2 (en) | 1998-04-03 | 2003-05-15 | University Of Iowa Research Foundation, The | Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
| WO2004030634A2 (en) | 2002-10-02 | 2004-04-15 | Alnylam Pharmaceuticals Inc. | Therapeutic compositions |
| CA2518475C (en) | 2003-03-07 | 2014-12-23 | Alnylam Pharmaceuticals, Inc. | Irna agents comprising asymmetrical modifications |
| WO2004090108A2 (en) | 2003-04-03 | 2004-10-21 | Alnylam Pharmaceuticals | Irna conjugates |
| US8969543B2 (en) | 2003-04-03 | 2015-03-03 | Bioneer Corporation | SiRNA-hydrophilic polymer conjugates for intracellular delivery of siRNA and method thereof |
| CA2521464C (en) | 2003-04-09 | 2013-02-05 | Alnylam Pharmaceuticals, Inc. | Irna conjugates |
| NZ542687A (en) | 2003-04-13 | 2010-02-26 | Enzon Pharmaceuticals Inc | Polymeric oligonucleotide prodrugs |
| US7851615B2 (en) | 2003-04-17 | 2010-12-14 | Alnylam Pharmaceuticals, Inc. | Lipophilic conjugated iRNA agents |
| JP4991288B2 (ja) | 2003-04-17 | 2012-08-01 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | 二本鎖ｉＲＮＡ剤、および二本鎖ｉＲＮＡ剤の対合の安定性を調節する方法。 |
| ES2702942T3 (es) | 2003-04-17 | 2019-03-06 | Alnylam Pharmaceuticals Inc | Agentes de ARNi modificados |
| US20100170000A9 (en) | 2004-10-25 | 2010-07-01 | Devgen Nv | Rna constructs |
| AU2006275579B2 (en) | 2005-08-01 | 2012-10-04 | Purdue Research Foundation | Multivalent RNA nanoparticles for delivery of active agents to a cell |
| KR101221589B1 (ko) | 2006-04-07 | 2013-01-15 | 이데라 파마슈티칼즈, 인코포레이티드 | Ｔｌｒ７ 및 ｔｌｒ８에 대한 안정화된 면역 조절성 ｒｎａ〔ｓｉｍｒａ〕 화합물 |
| US20080214436A1 (en) | 2007-01-26 | 2008-09-04 | City Of Hope | Methods and compositions for the treatment of cancer or other diseases |
| US8748405B2 (en) | 2007-01-26 | 2014-06-10 | City Of Hope | Methods and compositions for the treatment of cancer or other diseases |
| US20080287383A1 (en) | 2007-03-02 | 2008-11-20 | Nastech Pharmaceutical Company Inc. | Nucleic acid compounds for inhibiting erbb gene expression and uses thereof |
| US20080311040A1 (en) * | 2007-03-06 | 2008-12-18 | Flagship Ventures | METHODS AND COMPOSITIONS FOR IMPROVED THERAPEUTIC EFFECTS WITH siRNA |
| EP2357231A2 (en) | 2007-07-09 | 2011-08-17 | Idera Pharmaceuticals, Inc. | Stabilized immune modulatory RNA (SIMRA) compounds |
| CA2721183C (en) | 2008-04-11 | 2019-07-16 | Alnylam Pharmaceuticals, Inc. | Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components |
| WO2010021720A1 (en) | 2008-08-19 | 2010-02-25 | Nektar Therapeutics | Conjugates of small-interfering nucleic acids |
| US8637194B2 (en) | 2008-09-02 | 2014-01-28 | Bio-Nano Power, Llc | Bio-nano power cells and their uses |
| CN102282155B (zh) | 2008-12-02 | 2017-06-09 | 日本波涛生命科学公司 | 磷原子修饰的核酸的合成方法 |
| US9745574B2 (en) | 2009-02-04 | 2017-08-29 | Rxi Pharmaceuticals Corporation | RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality |
| JP5529895B2 (ja) * | 2009-02-04 | 2014-06-25 | ソンギュングヮン ユニバーシティ ファウンデーション フォー コーポレート コラボレーション | 細胞内の伝達能が増加した低分子干渉ｒｎａ複合体 |
| KR101141544B1 (ko) | 2009-03-13 | 2012-05-03 | 한국과학기술원 | 에스아이알엔에이 다중 접합체 및 이의 제조방법 |
| EP2470656B1 (en) | 2009-08-27 | 2015-05-06 | Idera Pharmaceuticals, Inc. | Composition for inhibiting gene expression and uses thereof |
| KR101678876B1 (ko) | 2010-01-15 | 2016-11-23 | 한국과학기술원 | 복합 유전자를 표적하는 ｓｉＲＮＡ 다중 접합체 및 이의 제조방법 |
| SI2539451T1 (sl) | 2010-02-24 | 2016-04-29 | Arrowhead Research Corporation | Sestavki za ciljano dostavo sirna |
| WO2011109380A1 (en) | 2010-03-01 | 2011-09-09 | The Children's Hospital Of Philadelphia | Nucleic acids for targeting multiple regions of the hcv genome |
| CN103796657B (zh) | 2011-07-19 | 2017-07-11 | 波涛生命科学有限公司 | 合成官能化核酸的方法 |
| AU2012308320C1 (en) | 2011-09-14 | 2018-08-23 | Translate Bio Ma, Inc. | Multimeric oligonucleotide compounds |
| KR101340290B1 (ko) * | 2011-09-14 | 2013-12-11 | 한국과학기술원 | 유전자 표적용 ｓｉＲＮＡ 하이드로젤 및 그 제조방법 |
| US20150247141A1 (en) | 2012-09-14 | 2015-09-03 | Rana Therapeutics, Inc. | Multimeric oligonucleotide compounds |
| US9956294B2 (en) | 2013-01-18 | 2018-05-01 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Targeted sensitization of non-del(5q) malignant cells |
| KR101629681B1 (ko) | 2013-06-24 | 2016-06-14 | 건국대학교 산학협력단 | 다중 리간드가 도입된 에스아이알엔에이 접합체 |
| GB201311840D0 (en) * | 2013-07-02 | 2013-08-14 | Univ Aberdeen | Control of varroa mite infestation |
| EP2845607A1 (en) | 2013-09-09 | 2015-03-11 | University of Vienna | Antisense oligonucleotides with improved pharmacokinetic properties |
| SG10201804960RA (en) | 2013-12-12 | 2018-07-30 | Alnylam Pharmaceuticals Inc | Complement component irna compositions and methods of use thereof |
| CA2935426C (en) | 2014-01-30 | 2023-07-25 | F. Hoffmann-La Roche Ag | Polyoligomer compound with biocleavable conjugates for reducing or inhibiting expression of a nucleic acid target |
| WO2016110691A1 (en) * | 2015-01-06 | 2016-07-14 | The University Court Of The University Of Aberdeen | Enhanced rnai mediated gene regulation |
| IL316159A (en) | 2015-06-15 | 2024-12-01 | Mpeg La Llc | Defined Oligonucleotide Multimers and Methods for Manufacture Thereof |
| US10758624B2 (en) | 2015-07-02 | 2020-09-01 | City Of Hope | Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof |
| WO2017075030A1 (en) | 2015-10-26 | 2017-05-04 | Rana Therapeutics, Inc. | Methods and compositions for increasing smn expression |
| KR102528260B1 (ko) | 2016-01-05 | 2023-05-04 | 유니버시티 오브 레스터 | 필요로 하는 대상체에서 섬유증의 억제 방법 |
| WO2018030338A1 (ja) | 2016-08-08 | 2018-02-15 | 浩文 山本 | アジュバント組成物 |
| SG11201906728TA (en) | 2017-02-06 | 2019-08-27 | Mpeg La Llc | Multimeric oligonucleotides having decreased kidney clearance |
| CN120330183A (zh) | 2017-06-02 | 2025-07-18 | 波涛生命科学有限公司 | 寡核苷酸组合物及其使用方法 |
| EP3733683A4 (en) | 2017-11-30 | 2022-04-06 | GeneMind Biosciences Company Limited | NUCLEOSIDE ANALOGUES, METHOD OF MANUFACTURE AND USE |
| EP3935168A4 (en) | 2019-03-04 | 2024-04-10 | Mpeg La, LLC | MULTIMERIC OLIGONUCLEOTIDES WITH IMPROVED BIOACTIVITY |
| JP2022543191A (ja) | 2019-07-30 | 2022-10-11 | エムペグ エルエイ リミテッド ライアビリティ カンパニー | 増強された生理活性を有する多量体オリゴヌクレオチドの皮下送達 |
| CA3178559A1 (en) | 2020-05-19 | 2021-11-25 | Jonathan Miles Brown | Orthogonally linked multimeric oligonucleotides |
-
2018
- 2018-02-06 SG SG11201906728TA patent/SG11201906728TA/en unknown
- 2018-02-06 JP JP2019542485A patent/JP7183167B2/ja active Active
- 2018-02-06 KR KR1020247000303A patent/KR102776167B1/ko active Active
- 2018-02-06 MX MX2019009347A patent/MX2019009347A/es unknown
- 2018-02-06 AU AU2018215684A patent/AU2018215684B2/en active Active
- 2018-02-06 WO PCT/US2018/017062 patent/WO2018145086A1/en not_active Ceased
- 2018-02-06 US US15/889,975 patent/US11078484B2/en active Active
- 2018-02-06 CN CN201880010283.4A patent/CN110248665A/zh active Pending
- 2018-02-06 IL IL307726A patent/IL307726A/en unknown
- 2018-02-06 KR KR1020197023090A patent/KR102623311B1/ko active Active
- 2018-02-06 EP EP18747398.8A patent/EP3576752A4/en active Pending
- 2018-02-06 CA CA3051480A patent/CA3051480A1/en active Pending
- 2018-02-06 IL IL267806A patent/IL267806B2/en unknown
-
2021
- 2021-07-01 US US17/305,225 patent/US12378551B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN110248665A (zh) | 2019-09-17 |
| US20180223284A1 (en) | 2018-08-09 |
| IL267806B1 (en) | 2023-11-01 |
| KR20240010750A (ko) | 2024-01-24 |
| KR102623311B1 (ko) | 2024-01-10 |
| JP7183167B2 (ja) | 2022-12-05 |
| KR20190115445A (ko) | 2019-10-11 |
| IL267806B2 (en) | 2024-03-01 |
| AU2018215684B2 (en) | 2024-03-07 |
| JP2020518552A (ja) | 2020-06-25 |
| AU2018215684A1 (en) | 2019-08-01 |
| US11078484B2 (en) | 2021-08-03 |
| WO2018145086A1 (en) | 2018-08-09 |
| IL267806A (en) | 2019-09-26 |
| US12378551B2 (en) | 2025-08-05 |
| US20210380979A1 (en) | 2021-12-09 |
| EP3576752A4 (en) | 2020-12-16 |
| KR102776167B1 (ko) | 2025-03-05 |
| EP3576752A1 (en) | 2019-12-11 |
| CA3051480A1 (en) | 2018-08-09 |
| MX2019009347A (es) | 2019-10-07 |
| SG11201906728TA (en) | 2019-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL267806A (en) | Multimeric oligonucleotides with reduced renal clearance | |
| IL266100A (en) | Multimeric il-15 based molecules | |
| IL256169A (en) | Multi-conjugated oligonucleotides are defined | |
| IL290070A (en) | pump | |
| GB2554254B (en) | Pump | |
| AU364477S (en) | Pump | |
| GB201503408D0 (en) | Oligonucleotides | |
| AU366816S (en) | Pump | |
| GB201504124D0 (en) | Oligonucleotides | |
| GB2554293B (en) | Pump | |
| GB201517241D0 (en) | DNA modification | |
| GB201518622D0 (en) | Pump | |
| GB2543832B (en) | Pump driver | |
| GB201714330D0 (en) | Oligonucleotides | |
| HK40015387A (en) | Multimeric oligonucleotides having decreased kidney clearance | |
| GB201506773D0 (en) | Pump | |
| GB201713546D0 (en) | DNA assembly | |
| GB201718608D0 (en) | Improved pump | |
| GB201707049D0 (en) | DNA Assembly | |
| GB201608069D0 (en) | Cavitation reduction | |
| GB201507865D0 (en) | Cavitation reduction | |
| PL3332121T3 (pl) | Pompa | |
| AU201612351S (en) | Pump | |
| GB201520883D0 (en) | Single molecule controls | |
| GB201502442D0 (en) | NTT passport |